Free Trial
NASDAQ:ENLV

Enlivex Therapeutics (ENLV) Stock Price, News & Analysis

Enlivex Therapeutics logo
$0.98 -0.05 (-4.87%)
(As of 11/20/2024 ET)

About Enlivex Therapeutics Stock (NASDAQ:ENLV)

Key Stats

Today's Range
$0.93
$1.11
50-Day Range
$0.98
$1.69
52-Week Range
$0.93
$4.59
Volume
388,159 shs
Average Volume
118,650 shs
Market Capitalization
$20.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00
Consensus Rating
Strong Buy

Company Overview

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Enlivex Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
62nd Percentile Overall Score

ENLV MarketRank™: 

Enlivex Therapeutics scored higher than 62% of companies evaluated by MarketBeat, and ranked 500th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Enlivex Therapeutics has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Enlivex Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Enlivex Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Enlivex Therapeutics are expected to grow in the coming year, from ($0.70) to ($0.58) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Enlivex Therapeutics is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Enlivex Therapeutics is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Enlivex Therapeutics has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.75% of the outstanding shares of Enlivex Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Enlivex Therapeutics has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Enlivex Therapeutics has recently increased by 58.67%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Enlivex Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Enlivex Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.75% of the outstanding shares of Enlivex Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Enlivex Therapeutics has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Enlivex Therapeutics has recently increased by 58.67%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Enlivex Therapeutics has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Enlivex Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    2 people have searched for ENLV on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Enlivex Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    12.28% of the stock of Enlivex Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 1.02% of the stock of Enlivex Therapeutics is held by institutions.

  • Read more about Enlivex Therapeutics' insider trading history.
Receive ENLV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enlivex Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ENLV Stock News Headlines

Enlivex Initiates Promising Trial for Psoriatic Arthritis
When it comes to NVDA… “acceleration cycles” are the key
Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.
Enlivex Advances Allocetra Trial for Knee Osteoarthritis
Enlivex Therapeutics Reschedules Annual Shareholders Meeting
See More Headlines

ENLV Stock Analysis - Frequently Asked Questions

Enlivex Therapeutics' stock was trading at $2.70 at the beginning of 2024. Since then, ENLV shares have decreased by 63.9% and is now trading at $0.9760.
View the best growth stocks for 2024 here
.

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) released its quarterly earnings results on Friday, August, 30th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.06.

Top institutional investors of Enlivex Therapeutics include Sigma Investment Counselors Inc. (0.14%).

Shares of ENLV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Enlivex Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Advanced Micro Devices (AMD), Arista Networks (ANET), CrowdStrike (CRWD), Adobe (ADBE) and Meta Platforms (META).

Company Calendar

Last Earnings
8/30/2024
Today
11/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ENLV
Employees
70
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.00
High Stock Price Target
$6.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+514.8%
Consensus Rating
Strong Buy
Rating Score (0-4)
3.50
Research Coverage
2 Analysts

Profitability

Net Income
$-29,070,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.62 per share

Miscellaneous

Free Float
18,777,000
Market Cap
$20.90 million
Optionable
Optionable
Beta
1.11
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

This page (NASDAQ:ENLV) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners